Sinonasal cancer in Denmark 2008–2015: a population-based phase-4 cohort study from DAHANCA

• DOI: 10.1080/0284186x.2021.1874618
• Publication Date: 2021-02-07T00:49:53Z
• Authors: Mads V. Filtenborg; Jacob K. Lilja-Fi...; Maja B. Sharma; Hanne Primdahl; Julie Kjems; Christina C. Plas...; Irene Wessel; Claus A. Kristensen; Maria Andersen; Elo Andersen; Christian Godballe; Jørgen Johansen; Jens Overgaard; Kristian B. Petersen
• Keywords: Cumulative incidence

Sinonasal cancer is considered a rare disease with poor survival. Its treatment has changed profoundly in recent years, primarily following the introduction of intensity-modulated radiation therapy (IMRT) and minimally invasive endoscopic surgery. Danish national guidelines on patients diagnosed sinonasal carcinoma were introduced 2007. The aim this phase-4 study was to assess effect implementation by describing outcomes consecutive nationwide cohort.All Denmark from 2008 2015 identified clinical database, DAHANCA, followed until May 2020. Overall survival (OS) analysed using Kaplan-Meier estimator. Cumulative incidence locoregional failure (LRF) disease-specific mortality (DSM) Aalen-Johansen Competing risks death other causes distant (LRF). Analysis prognostic factors performed Cox proportional hazard analysis. Start follow-up time diagnosis. results are presented as estimates 95% confidence intervals (95% CIs).A total 331 identified. Curatively intended 264 (80%). Non-compliance registered 24 (9%). associated LRF (hazard ratio [HR], 2.0 [95% CI: 1.1-3.5]). Among qualified for curative treatment, occurred 109 (41%), at primary tumour site (81%). Anatomical stage independent factors. 5-year OS 56% treated intent, combined strategy showed reduced (HR, 0.53 0.30-0.92]) multivariate analysis.Guideline compliance approach thereby increased OS. Our confirm those international studies. Treatment remains challenge that requires multidisciplinary team coordination.